PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID, FOR INDUCTION OF INTERFERON IN PRIMATES

摘要

16336IA TITLE OF THE INVENTION Pharmaceutical Composition Comprising Modified Polyriboinosinic-Polyribocytidylic Acid, for Induction of Interferon in Primates. A complex of polyriboinosinic-polyribocytidylic acid (poly I:C) with poly-L-lysine hydrobromide (¢lysine.HBr!n) having a defined molecular weight is prepared which is about 5-15 times as resistant to hydrolysis by pancreatic ribonuclease as the parent poly I:C. A pharmaceutical solution, containing a relatively high concentration of the complex, prepared as described, induces significant antiviral levels of serum interferon in monkeys under conditions in which poly I:C itself induces little or no interferon. An important feature of this invention is that the product is a soluble material requiring no special solubilizing agent, thereby facilitating the preparation of solutions having the desired concentration. The product will hereinafter be designated as poly I:C/poly-L-lysine.